Goodrx’s 2026 Q2 Earnings Call: Buyback Contradictions and Margin Signals Don’t Align

<<>>

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $200.4 million
• Operating Margin: 31.8% adjusted EBITDA margin

Guidance:

• Full year revenue guidance raised to $790 to $805 million, with return to year-over-year growth earlier than anticipated.
• PharmaDirect revenue expected to grow more than 70% year-over-year.
• Full year adjusted EBITDA guidance raised to $240 to $250 million.

Business Commentary:

Revenue and Earnings Growth:

• GoodRx reported revenue of $200.4 million and adjusted EBITDA of $63.7 million for Q2 2026, with an adjusted EBITDA margin of 31.8%.
• The growth was driven by momentum in the PharmaDirect and subscriptions offerings, which are becoming a larger portion of overall revenue.

PharmaDirect Performance:

• PharmaDirect revenue was $61.6 million, up 76% year-over-year.
• The increase was due to deeper manufacturer partnerships and the expansion of consumer direct pricing programs, with significant contributions from GLP-1 access programs.

Subscription Growth:

• Subscription revenue increased to $28.5 million, up 39% year-over-year, with the number of subscription plans increasing by 14%.
• This growth was driven by strong demand for condition-specific offerings, particularly weight loss, and the launch of GoodRx Companion in May.

Leadership Transition:

• Chris McGinnis transitioned from his role as Chief Financial Officer, and Justin Singler was appointed as the new CFO.
• This transition was part of GoodRx's strategic focus on scaling programs and improving execution, leveraging Justin's experience in finance and corporate strategy.

Consumer Engagement and Market Position:

• GoodRx recorded over 280 million site visits in the year, indicating strong consumer engagement.
• The company's strategic focus on expanding its pharmacy network and offering integrated savings programs contributed to its market position and ability to attract manufacturer partnerships.

Sentiment Analysis:

Overall Tone: Positive

• Management described Q2 as a 'strong quarter' with revenue exceeding expectations, raised full-year outlook, and stated 'our strategy is working.' They highlighted 'meaningful consumer engagement' and growth in key initiatives like PharmaDirect and subscriptions, noting they are 'confident' in a 'more durable growth profile.'

Q&A:

• Question from Charles Ryee (TD Cowan): Concerns about overall performance metrics and prescription fill data, and request for more relevant KPIs as the business transitions from transactional to subscription-based.
  Response: Management acknowledged the need to evaluate new KPIs but stated it is too early to announce changes; they emphasized long-term durable revenue and the ongoing transition to subscriptions and PharmaDirect.

• Question from Daniel Grossleit (Citi): Inquiry about the importance of GLP-1s to PharmaDirect growth and sustainable growth rate for the segment.
  Response: GLP-1s are an important part of PharmaDirect growth and will remain so, but non-GLP-1 partnerships are also growing strongly; the segment is expected to be very strong this year with continued long-term strength.

• Question from Michael Cherney (Lear Inc.): Asked about capacity constraints and incremental investments needed to support PharmaDirect ramp.
  Response: No significant incremental costs anticipated; the team and infrastructure are already in place to scale PharmaDirect with minimal additional investment.

• Question from Stan Bernstein (Wells Fargo Securities): Asked about PharmaDirect pipeline activity for the balance of the year and gross margin expectations.
  Response: Bookings are largely set for the year; gross margin is not guided, with increased cost of revenue partly due to subscription offerings but no material changes expected.

• Question from Jalendra Singh (Truist Securities): Asked if coverage changes (Medicaid, ACA) are impacting the business and thoughts on the peptide market opportunity.
  Response: Coverage changes are seen as tailwinds for companion and traditional coupon usage, but no definitive impact on volume yet; peptide market is of interest but requires FDA regulatory approval.

• Question from Craig Hettenbach (Morgan Stanley): Asked about retention and churn trends for condition-specific offerings and early read on GLP-1 persistence.
  Response: Retention is not a disclosed KPI; subscription revenue grew 39% YOY with early strong progress for new Companion offering, indicating good retention and ARPU trends.

• Question from Brian Tankolet (Jefferies): Asked about capital allocation given strong free cash flow and buyback activity.
  Response: Capital allocation priorities remain investing in the business, particularly in subscriptions and PharmaDirect, with M&A considered opportunistically.

• Question from Alan Lutz (Bank of America): Asked for expectations on prescription transaction revenue (PTR) and MACD, and offsetting subscription revenue and growth.
  Response: PTR is expected to moderate as more consumers shift to subscriptions; focus is on long-term durability and product development, not short-term revenue optimization.

• Question from George Hill (Deutsche Bank): Asked about positioning of Companion and EmployerDirect offerings and navigating partnership relationships.
  Response: EmployerDirect is positioned as a complement to benefits, focusing on GLP-1s where coverage is lacking; Companion serves as an affordable alternative health plan complement, with no significant PBM pushback observed.

• Question from Stephen Valliquette (Mizuho Securities): Asked about impact of strong generic drug launches on the business and potential for greater leverage.
  Response: Generics are the majority of fills and crucial for companion offerings; the company remains committed to driving competitive generic pricing and will not abandon this focus.

Contradiction Point 1

Capital Allocation Priorities

Contradiction on the execution status of buybacks within the stated capital allocation framework.

Brian Tanquilut (Jefferies) - Brian Tanquilut (Jefferies)

2026Q2: Capital allocation priorities remain unchanged... No buybacks were executed in Q2. - [Justin Fengler](CFO)

How are you allocating capital given strong free cash flow, recent buybacks, and current stock valuation? - Steven Valiquette (Mizuho Securities)

2026Q2: Given strong free cash flow and the recent buyback, how are you thinking about capital allocation... - [Brian Tanquilut](Jefferies)

Contradiction Point 2

Gross Margin Expectations

Inconsistency regarding the company's guidance stance on gross margin, specifically in the context of subscription offerings.

Stan Rosenstein (Wells Fargo Securities) - Stan Rosenstein (Wells Fargo Securities)

2026Q2: The company does not guide to a specific number; cost of revenue has increased due to subscription offerings but is not expected to change materially through the rest of the year. - [Wendy Barnes](CFO)

How active is the Pharma Direct pipeline for the balance of the year compared to last year, and what are the expected gross margin trends given the revenue mix? - Stan Bernstein (Wells Fargo Securities)

2026Q2: The increase in cost-to-revenue year-over-year is partly due to serving subscription offerings, which are becoming a larger part of the mix. - [Justin Fengler](CFO)

Contradiction Point 3

Subscription Revenue Growth Trajectory

Inconsistent portrayal of subscription revenue growth momentum between quarters.

What are Bank of America's earnings highlights? - Alan Lutz (Bank of America)

2026Q2: Subscription revenue growth (39% year-over-year) and plan growth (17% quarter-over-quarter) are positive indicators, and the company expects these metrics to improve sequentially as the new offerings mature. - [Justin Singler](CFO)

What are the expected PTR and MAC revenue trends over the next few quarters, and how will subscription revenue and growth offset potential declines? - Allen Lutz (Bank of America)

2026Q1: The launch demonstrated the power of a well-coordinated cash/point-of-sale strategy with Novo. Demand for GLP-1s remains strong. GoodRx expects continued performance... - [Wendy Barnes](CEO)

Contradiction Point 4

PTR/MAC Performance and Outlook

Contradiction on whether PTR decline is moderating or remains stable as a comp.

Alan Lutz (Bank of America) - Alan Lutz (Bank of America)

2026Q2: The company is actively shifting consumers to subscription offerings... which is expected to cause continued moderation in PTR/MAC. - [Justin Singler](CFO)

What are the expectations for prescription transaction revenue (PTR) and MAC in the coming quarters, and how will subscription revenue and growth address potential declines? - Craig Hettenbach (Morgan Stanley) - via Jaye

2026Q1: Q1's ~24% year-over-year decline is indicative of the expected comp for 2026. The business is watching macroeconomic factors... MAC could potentially stabilize or flatten in 2026. - [Chris McGinnis](CFO)

Contradiction Point 5

Strategic Outlook on PTR/MAC Metrics and Business Model Shift

Contradiction on the impact and management of core transaction metrics.

Charles Ryee (TD Cowan) - Charles Ryee (TD Cowan)

2026Q2: The company acknowledges the limitations of using Monthly Active Consumers (MAC) as a primary metric, as it only reflects prescription transaction revenue. The focus is transitioning to subscriptions... - [Wendy Barnes](CEO)

Can you provide metrics on prescriptions filled across PTR, PharmaDirect, and subscriptions, as well as investor-focused growth metrics considering PTR's decline? - Michael Cherny (Leerink Partners LLC)

2025Q4: The decline in PTR is driven by... a deliberate reset of unit economics through renegotiations for longer-term durability, which is a mid-single-digit percentage headwind to consolidated revenue. - [Christopher McGinnis](CFO)

<<>>